Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.

Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. J Thorac Oncol. 2013 Dec; 8(12):e105-6.

View in: PubMed

subject areas

Adenocarcinoma
Aged
Antineoplastic Agents
DNA, Neoplasm
Drug Resistance, Neoplasm
ErbB Receptors
Female
Gene Dosage
Humans
In Situ Hybridization, Fluorescence
Lung Neoplasms
Mutation
Prognosis
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Proto-Oncogene Proteins
Proto-Oncogene Proteins c-met
Pyrazoles
Pyridines
Quinazolines
Receptor Protein-Tyrosine Kinases
Salvage Therapy

authors with profiles

Marina Chiara Garassino